[1]陈 涛,孙晶琳,张 健,等.PCSK9抑制剂在冠状动脉粥样硬化性心脏病 治疗中的应用[J].医学信息,2019,(17):39-41.[doi:10.3969/j.issn.1006-1959.2019.16.013]
 CHEN Tao,SUN Jing-lin,ZHANG Jian,et al.Application of PCSK9 Inhibitor in the Treatment of Coronary Atherosclerotic Heart Disease[J].Medical Information,2019,(17):39-41.[doi:10.3969/j.issn.1006-1959.2019.16.013]
点击复制

PCSK9抑制剂在冠状动脉粥样硬化性心脏病 治疗中的应用()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年17期
页码:
39-41
栏目:
综述
出版日期:
2019-09-01

文章信息/Info

Title:
Application of PCSK9 Inhibitor in the Treatment of Coronary Atherosclerotic Heart Disease
文章编号:
1006-1959(2019)16-0039-03
作者:
陈 涛孙晶琳张 健齐向前
泰达国际心血管病医院心内科,天津 300457
Author(s):
CHEN TaoSUN Jing-linZHANG JianQI Xiang-qian
Department of Cardiology,TEDA International Cardiovascular Hospital,Tianjin 300457,China
关键词:
蛋白转化酶枯草溶菌素9PCSK9抑制剂LDL-C动脉粥样硬化性
Keywords:
Key words:Protein converting enzyme subtilisin 9PCSK9 inhibitorLDL-CAtherosclerosis
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2019.16.013
文献标志码:
A
摘要:
低密度脂蛋白胆固醇(LDL-C)血浆水平升高是动脉粥样硬化性心血管疾病(ASCVD)的主要危险因素。他汀类药物虽然能够有效降低 LDL-C水平,但仍有部分患者无法达到降脂目标或者无法耐受。目前大量研究表明前蛋白转化酶枯草溶菌素9(PCSK9)与血浆LDL-C紧密相关,抑制PCSK9可以有效降低LDL-C水平及ASCVD发生率。本文主要对PCSK9机制以及PCSK9抑制剂治疗冠状动脉粥样硬化性心脏病的新研究进展作一综述。
Abstract:
Abstract:Elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) are a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins can effectively reduce LDL-C levels, some patients are still unable to achieve lipid-lowering goals or are intolerable. A large number of studies have shown that the proprotein convertase subtilisin 9 (PCSK9) is closely related to plasma LDL-C, and inhibition of PCSK9 can effectively reduce the level of LDL-C and ASCVD. This article reviews the recent advances in PCSK9 mechanisms and PCSK9 inhibitors in the treatment of coronary atherosclerotic heart disease.

参考文献/References:

[1]Dadu RT,Ballantyne CM.Lipid lowering with PCSK9 inhibitors[J].Nature Reviews Cardiology,2014,11(10):563-575. [2]Tibolla G,Norata GD,Artali R,et al.Proprotein convertase subtilisin/kexin type 9(PCSK9):from structure-function relation to therapeutic inhibition[J].Nutr Metab Cardiovasc Dis,2011,21(11):835-843. [3]Bergeron N,Phan BA,Ding Y,et al.Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk[J].Circulation,2015,132(17):1648. [4]Cicero AF,Colletti A,Borghi C.Profile of evolocumab and its potential in the treatment of hyperlipidemia[J].Drug Des Devel Ther,2015(9):3073-3082. [5]Robinson JG,Nedergaard BS,Rogers WJ,et al.Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia:The LAPLACE-2 Randomized Clinical Trial[J].JAMA,2014,311(18):1870-1873. [6]Koren MJ,Lundqvist P,Bolognese M,et al.Anti-PCSK9 monotherapy for hypercholesterolemia:the MENDEL-2 randomized,controlled phase Ⅲ clinical trial of evolocumab[J].Journal of the American College of Cardiology,2014,63(23):2531-2540. [7]Stroes E,Colquhoun D,Sullivan D,et al.Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance:the GAUSS-2 randomized,placebo-controlled phase 3 clinical trial of evolocumab[J].Journal of the American College of Cardiology,2014,63(23):2541-2548. [8]Chaudhary R,Garg J,Shah N,et al.PCSK9 inhibitors:A new era of lipid lowering therapy[J].World Journal of Cardiology,2017,9(2):76-91. [9]Sabatine MS,Giugliano RP,Wiviott SD,et al.Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events[J].N Engl J Med,2015,372(16):1500-1509. [10]Schulz R,Klaus-Dieter Schlüter,Laufs U.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9(PCSK9)[J].Basic Res Cardiol,2015,110(2):4. [11]Seidah NG,Sadr MS,Chretien M,et al.The Multifaceted Proprotein Convertases:Their Unique, Redundant,Complementary,and Opposite Functions[J].J Biol Chem,2013,288(30):21473-21481. [12]Jaworski K,Jankowski P,Kosior DA.PCSK9 inhibitors-from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade[J].Archives of Medical Science Ams,2017,13(4):914-929. [13]Zhang DW,Lagace TA,Garuti R,et al.Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation[J].Journal of Biological Chemistry,2007,282(25):18602-18612. [14]Yamamoto T,Lu C,Ryan RO.A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor[J].Journal of Biological Chemistry,2011,286(7):5464-5470. [15]Surdo PL,Bottomley MJ,Calzetta A,et al.Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH[J].Embo Reports,2011,12(12):1300-1305. [16]Rashid H,Meredith IT,Nasis A.PCSK9 Monoclonal Antibodies in 2016:Current Status and Future Challenges[J].Heart Lung&Circulation,2017,26(8):786-798. [17]Sabatine MS,Giugliano RP,Wiviott SD,et al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1489-1499. [18]Schwartz GG,Steg PG,Szarek M,et al.Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J].N Engl J Med,2018,379(22):2097-2107. [19]Nicholls SJ,Puri R,Anderson T,et al.Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients:The GLAGOV Randomized Clinical Trial[J].JAMA,2016,316(22):2373-2384. [20]Sabatine MS,Giugliano RP,Keech AC,et al.Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease[J].N Engl J Med,2017,376(18):1713-1722.

更新日期/Last Update: 2019-09-01